| Soluble vascular endothelial growth factor receptor-1 in intrauterine growth restricted fetuses and neonates. | |
| | |
MedLine Citation:
|
PMID: 16337100 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Angiogenesis, a critical process for growth and development is altered in intrauterine growth restriction (IUGR). Vascular endothelial growth factor (VEGF) and its receptors VEGFR-1, soluble (s) VEGFR-1 and VEGFR-2 represent a regulatory system, essential for both physiological and pathological angiogenesis. AIM: To study the implication of sVEGFR-1-a VEGF antagonist-in IUGR. STUDY DESIGN: Prospective study. METHODS: Twenty-five IUGR and 15 appropriate for gestational age (AGA) full-term fetuses and neonates with their mothers were included in the study. OUTCOME MEASURES: sVEGFR-1 levels were determined by enzyme immunoassay in the serum of: mothers (MS), umbilical cords (UC)-representing fetal state - and neonates on day 1 (N1) and 4 (N4) of life. RESULTS: MS, UC, N1 and N4 sVEGFR-1 levels in IUGR were significantly higher compared to respective AGA cases (p = 0.005, p = 0.026, p = 0.005 and p = 0.017, respectively). In IUGR and AGA groups, maternal sVEGFR-1 levels were significantly higher than fetal and neonatal levels (p in all cases < 0.001). The latter presented in both IUGR and AGA groups a significant decrease from UC to N4 (p in all cases < 0.01). MS, N1 and N4 sVEGFR-1 levels negatively correlated with the infants' customized centiles [(r = -0.489, p = 0.001), (r = -0.440, p = 0.004), (r = -0.431, p = 0.006), respectively]. CONCLUSIONS: Higher sVEGFR-1 levels in the IUGR as compared to the AGA group possibly reflect the predominance of antiangiogenic mechanisms present in IUGR. The decrease of sVEGFR-1 levels from UC to N4 may represent ex utero initiation of growth and development and therefore, prevalence of angiogenic mechanisms. |
| | |
Authors:
|
Theodora Boutsikou; Ariadne Malamitsi-Puchner; Emmanuel Economou; Maria Boutsikou; Karl-Philipp Puchner; Dimitrios Hassiakos |
Publication Detail:
|
Type: Journal Article Date: 2005-12-05 |
Journal Detail:
|
Title: Early human development Volume: 82 ISSN: 0378-3782 ISO Abbreviation: Early Hum. Dev. Publication Date: 2006 Apr |
Date Detail:
|
Created Date: 2006-04-21 Completed Date: 2006-07-06 Revised Date: 2009-11-19 |
Medline Journal Info:
|
Nlm Unique ID: 7708381 Medline TA: Early Hum Dev Country: Ireland |
Other Details:
|
Languages: eng Pagination: 235-9 Citation Subset: IM |
Affiliation:
|
Neonatal Division, 2nd Department of Obstetrics and Gynecology, University of Athens 19, Soultani Str GR-10682, Athens, Greece. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Female Fetal Blood / metabolism Fetal Growth Retardation / blood* Fetus / metabolism* Gestational Age Humans Infant, Newborn / blood* Male Pregnancy / blood Prospective Studies Reference Values Vascular Endothelial Growth Factor Receptor-1 / blood* |
| Chemical | |
Reg. No./Substance:
|
EC 2.7.10.1/Vascular Endothelial Growth Factor Receptor-1 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The association between early minor motor difficulties in extreme low birth weight infants and schoo...
Next Document: A comparative study on lipid peroxidation, activities of antioxidant enzymes and viability of cattle...